Mexiletin (2) – Namuscla®
Myotonia, 6 to ≤ 17 years, ≥ 20 kg
Characteristics
| Start date | 15.06.2026 |
|---|---|
| Resolution | 03.12.2026 – active procedure |
| INN | Mexiletin |
| Brand name | Namuscla® |
| Pharm. company | Lupin Europe GmbH |
| G-BA Procedure ID | D-1322 |
| Therapeutic area | Nervous system diseases Orphan |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Mexiletin (2) | Namuscla® | Lupin Europe GmbH | Myotonia, 6 to ≤ 17 years, ≥ 20 kg | n.d. | active procedure Orphan | |
| Mexiletin (1) | Namuscla® | Lupin Europe GmbH | Myotonia | 530–650 | 100% non-quantifiable additional benefit Orphan |
<< List of all resolutions